fibrinogenkoncentrat

Fibrinogenkoncentrat is a pharmaceutical preparation derived from human plasma that contains concentrated fibrinogen. Fibrinogen is a protein that plays a crucial role in the blood clotting cascade. It is synthesized in the liver and is converted into fibrin by the enzyme thrombin, forming the meshwork that stabilizes a blood clot. Fibrinogenkoncentrat is used therapeutically to treat or prevent bleeding in patients with severe fibrinogen deficiency. This deficiency can be congenital, such as in afibrinogenemia or hypofibrinogenemia, or acquired due to conditions like disseminated intravascular coagulation (DIC) or massive hemorrhage. The administration of fibrinogenkoncentrat aims to rapidly increase plasma fibrinogen levels, thereby restoring the blood's ability to form stable clots. It is typically administered intravenously. The product is subject to rigorous screening and manufacturing processes to ensure its safety and efficacy, including testing for viral pathogens. Like all blood-derived products, potential risks include allergic reactions and transmission of infectious agents, although these are minimized through stringent safety measures. Fibrinogenkoncentrat is an important component of modern hemostatic therapy.